Capricor Therapeutics (CAPR) Tops Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts CAPR Hot Sheet
Join SI Premium – FREE
Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.16), $0.02 better than the analyst estimate of ($0.18).
For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
- Jefferies bullish on Deckers Outdoor, sees HOKA growth slowdown as oversold
- Truist upgrades Biogen to Buy on Alzheimer's, pipeline optimism ahead of key data
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
